Pasithea Therapeutics (KTTA) vs Lipocine (LPCN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pasithea Therapeutics (KTTA) has outperformed Lipocine (LPCN) over the past year, losing 40.8% versus a loss of 45.4%. Over five years, LPCN leads with a -91.0% price change compared with -99.2% for KTTA. Pasithea Therapeutics is the larger company by market cap ($15.6 million vs $14.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KTTA | LPCN |
|---|---|---|
| Share price | $0.4675 | $1.72 |
| Market cap | $15.62M | $14.18M |
| 1-day change | +6.03% | -10.88% |
| YTD return | -63.76% | -78.58% |
| 1-year return | -40.82% | -45.40% |
| 5-year return | -99.22% | -91.05% |
| EPS (TTM) | $-1.59 | $-1.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.06 | $12.37 |
| 52-week low | $0.281 | $1.72 |
| Distance from 52-week high | -77.31% | -86.10% |
| Analyst consensus | none | none |
| Avg. price target upside | +541.71% | +190.70% |
| Average volume | 225.69K | 1.72M |
| Shares outstanding | 33.41M | 8.24M |
| Employees | 5 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Lipocine
LPCN stock →Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
KTTA vs LPCN FAQ
Which is bigger, Pasithea Therapeutics or Lipocine?
Pasithea Therapeutics (KTTA) is larger, with a market capitalization of $15.62M compared with $14.18M for Lipocine (LPCN).
Which stock has performed better over the past year, KTTA or LPCN?
KTTA returned -40.82% over the past 12 months, compared with -45.40% for LPCN (price return, excluding dividends). Past performance does not predict future results.
Are Pasithea Therapeutics and Lipocine in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.